Pacira BioSciences director tenders 11,393 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacira BioSciences, Inc. (PCRX) director Marcelo Bigal reported dispositions on November 17, 2026, in connection with the Viatris merger. He disposed of 11,393 common shares in the cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. His 6,405 shares issuable under restricted stock unit awards were canceled and converted into cash, subject to tax withholding.
Four option awards were canceled and converted into cash based on the excess, if any, of the $36.50 offer price over each exercise price: 12,179 options at $28.68; 11,279 at $24.34; 10,891 at $23.42; and 30,967 at $29.80 per share.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F3 | 12,179 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3 | 11,279 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3 | 10,891 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3 | 30,967 | -- | -- |
| Tender Offer | Common Stock F1 | 11,393 | $36.50 | $416K |
| Disposition | Common Stock F2 | 6,405 | $36.50 | $234K |
Footnotes (3)
- F1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
- F2. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
- F3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Key Figures
Key Terms
cash tender offer financial
restricted stock unit award financial
Effective Time technical
Offer Price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happened to Marcelo Bigal's PCRX stock options in the Viatris merger?
What happened to Marcelo Bigal's PCRX restricted stock units?
AI-generated analysis. How Rhea-AI works. Not financial advice.